McKesson Corporation (MCK) – FY2025 Form 10-K Analysis

What happened

McKesson reported revenues of $359.1 billion for fiscal 2025, up 16% from $309.0 billion in fiscal 2024. Gross profit increased 4% to $13.3 billion, though gross margin compressed 44 basis points to 3.71%, reflecting a $82 million LIFO inventory charge in fiscal 2025 compared to a $157 million LIFO credit in the prior year. Total operating expenses remained essentially flat at $8.9 billion despite the revenue increase, representing improved operating leverage as expenses declined 41 basis points as a percentage of revenue to 2.48%. However, operating expenses for fiscal 2025 included $667 million in charges to remeasure the Canadian retail disposal group to fair value less costs to sell and $298 million in restructuring charges. Net income attributable to McKesson increased 10% to $3.3 billion, and diluted earnings per share rose 15% to $25.72, benefiting from share count reduction. Operating cash flow strengthened to $6.1 billion from $4.3 billion, reflecting improved working capital management and higher net income. The company received $444 million in antitrust settlement proceeds during the year, up from $244 million in the prior year, and reversed $206 million of previously reserved Rite Aid receivables following reassessment of prepetition balances. The reported income tax rate increased to 20.1% from 16.6%, though this included a $258 million discrete tax benefit from intellectual property transfers between foreign subsidiaries.

Why it matters for investors

The results demonstrate McKesson's ability to convert substantial revenue growth into meaningful profit expansion despite significant one-time charges and margin headwinds. The U.S. Pharmaceutical segment's 44% operating profit growth on 18% revenue growth signals improving unit economics, driven by specialty pharmaceutical expansion and retail national account penetration. The $444 million in antitrust settlement proceeds and $206 million Rite Aid reversal provided meaningful earnings tailwinds, though these are non-recurring. The swing from a LIFO credit to a LIFO charge of $82 million reflects accelerating brand pharmaceutical inflation, which may indicate pricing power returning to the supply chain. The $667 million impairment of the Canadian retail disposal group and $298 million in restructuring charges represent strategic portfolio rationalization and operational efficiency initiatives intended to streamline the business for sustainable growth. Operating cash flow expansion of $1.8 billion to $6.1 billion demonstrates strong cash conversion and improved working capital dynamics. The company's capital allocation remains heavily weighted toward shareholder returns, deploying $3.5 billion through buybacks and dividends, which contributed to the 4% reduction in diluted share count and amplified per-share earnings growth. The 10% dividend increase signals management confidence in cash generation sustainability. The International segment's swing to a $213 million operating loss from $319 million profit is primarily driven by the Canadian disposal charges and represents portfolio cleanup rather than operational deterioration. The Medical-Surgical segment's margin compression of 163 basis points and 19% profit decline on minimal revenue growth, combined with $204 million in restructuring charges, suggests this business faces structural challenges, consistent with management's May 2025 announcement to separate it into an independent company.

Key highlights

McKesson completed the sale of its Canadian retail disposal group (Rexall and Well.ca) on December 30, 2024 for adjusted consideration of $9 million cash and a $120 million note receivable. The company onboarded a new strategic partner within U.S. Pharmaceutical during fiscal 2025. McKesson announced on April 2, 2025 the completion of its acquisition of an approximate 80% controlling interest in PRISM Vision Holdings, a provider of ophthalmology and retina management services, to be reported within U.S. Pharmaceutical. The company entered into a definitive agreement in August 2024 to acquire a 70% controlling interest in Core Ventures for approximately $2.49 billion, expected to close in the first quarter of fiscal 2026. In May 2025, McKesson announced its intention to separate the Medical-Surgical Solutions segment into an independent company. The company issued $500 million of 4.25% Notes due September 2029 and redeemed $500 million of 5.25% Notes due February 2026 prior to maturity. Customer concentration remains significant with the largest customer (CVS) representing 24% of total revenues and 23% of trade receivables, and the ten largest customers representing 72% of revenues and 48% of receivables. Rite Aid filed a second bankruptcy petition in May 2025 following its emergence in August 2024.

Management commentary

Management stated in the Executive Summary that the company is 'a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere' and that 'teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.' Management explained that the $667 million charge for the Canadian retail disposal group remeasurement 'includes a $48 million loss related to the accumulated other comprehensive loss balances associated with the disposal.' Regarding Rite Aid, management noted they 'reassessed our initial estimates made in conjunction with the previously reserved prepetition balances, including cash received during the period, resulting in a reversal of $206 million' and stated they 'believe the reserves maintained and any adjustments recorded for Rite Aid trade accounts receivable are appropriate and consistent with our accounting policy and assessment of the information currently available.' For opioid litigation, management disclosed an estimated accrued liability of $6.4 billion as of March 31, 2025 and stated 'we are not able to reasonably estimate the upper or lower ends of the range of ultimate possible losses for all opioid-related litigation matters.' On restructuring, management stated the enterprise-wide initiatives are 'intended to improve business continuity, compliance, operating efficiency and advance investments to streamline the organization' with 'total charges related to these initiatives of $650 million to $700 million' and programs 'anticipated to be substantially complete in fiscal 2028.' Management noted their business strategy 'includes investing to build an integrated oncology and specialty care platform and expand our biopharma services business.'

What to watch next

Investors should monitor:

• Completion timing and integration success of the Core Ventures acquisition (expected first quarter fiscal 2026) for approximately $2.49 billion, which will significantly expand the oncology platform within U.S. Pharmaceutical

• Execution of the Medical-Surgical Solutions separation into an independent company following the May 2025 announcement, including transaction structure, timing, and impact on McKesson's portfolio and capital allocation

• Restructuring program progress through fiscal 2028 with anticipated total charges of $650-$700 million, and whether operational efficiencies materialize to offset near-term margin pressure

• Trajectory of opioid litigation settlements and cash payment obligations against the $6.4 billion accrued liability, particularly given management's statement that ultimate losses cannot be reasonably estimated and any adverse outcomes could materially impact financial position

• LIFO inventory accounting impacts as brand pharmaceutical inflation trends may continue to pressure gross margins, given the swing from a $157 million credit in fiscal 2024 to an $82 million charge in fiscal 2025

This summary is based solely on excerpts from the company's Form 10-K filing.